Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03248882 · ClinicalTrials.gov registry record · Phase 2

Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

A Phase 2 study, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
305
Enrollment target

NCT03248882 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 305 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03248882, a Phase 2 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
305 participants
Enrollment target

Study Summary

Phase 2a, dose-ranging Study with PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

Interventions

  • DRUG Placebo
  • DRUG PF-05221304

Trial Details

FieldValue
Enrollment Target 305 participants
Start Date 2017-08-22
Est. Completion 2019-03-27
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT03248882

The ClinicalTrials.gov registry entry for NCT03248882 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 305 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT03248882 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03248882 about?

NCT03248882 is a clinical study titled "Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)". Phase 2a, dose-ranging Study with PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

What is the current status of trial NCT03248882?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 305 participants. The study started on 2017-08-22. Estimated completion is 2019-03-27.

What interventions are being tested in trial NCT03248882?

The interventions under investigation include: Placebo (DRUG), PF-05221304 (DRUG).

Who is sponsoring clinical trial NCT03248882?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.